Clinical Trials Logo

Secondary clinical trials

View clinical trials related to Secondary.

Filter by:
  • None
  • Page 1

NCT ID: NCT03226236 Withdrawn - Clinical trials for Carcinoma, Renal Cell

Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC

RENALVax-2
Start date: March 2016
Phase: Phase 2
Study type: Interventional

Single center, open-label Proof of Principle phase II trial to assess objective response (ORR). Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2. The first day of administration of vaccine is day +1 and of IL-2 is day +2. Treatment vaccine plus IL-2 (dose 18 MIU/m2/day in 500cc by continuous IV infusion for 72 hours) will be administered every 3 weeks up to 6 cycles. Total duration of the trial: 36 months - Enrolment period: 24 months - Treatment: maximum of 6 cycles (5 months) per patient - Follow-up every three months until patient died (follow-up until PD and only survival contacts and subsequent therapy for metastatic disease after PD).

NCT ID: NCT02919462 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression

HighTySy
Start date: March 2016
Phase: Phase 2
Study type: Interventional

This is an open-label, multicentre, randomized phase II trial. Eligible patients with Non Small Cell Lung Cancer (NSCLC) with high Thymidylate Synthase (TS) expression , will be randomly assigned with 1:1 ratio to the following treatment Arms: A. 4 cycles of Cisplatin + Oral Vinorelbine followed by maintenance with Metronomic Oral Vinorelbine until disease progression B. 4 cycles of Cisplatin + Pemetrexed followed by maintenance with Pemetrexed until disease progression Treatment will be repeated every 21 days .

NCT ID: NCT02716766 Completed - Clinical trials for Carcinoma, Hepatocellular

Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)

Start date: March 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if sorafenib, capecitabine and oxaliplatin (SECOX) regimen is more effective than sorafenib alone in the treatment of advanced liver cancer.

NCT ID: NCT02067143 Completed - Secondary Clinical Trials

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate

LAL1913
Start date: May 20, 2014
Phase: Phase 2
Study type: Interventional

This study will be conducted in different centres and will study adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). The study treatment will include a induction/consolidation therapy incorporating pegylated Asparaginase (Peg-ASP) and lineage-targeted high-dose methotrexate plus other antileukemic drugs, for the achievement of an early negative minimal residual disease (MRD) status. The MRD study supports a risk/MRD-oriented final consolidation phase.

NCT ID: NCT01420146 Completed - Breast Neoplasms Clinical Trials

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients

IJBMNZrT003
Start date: August 2011
Phase: Phase 1
Study type: Interventional

Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab.

NCT ID: NCT00507143 Recruiting - Clinical trials for Colorectal Neoplasms

Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan

Start date: August 2006
Phase: N/A
Study type: Interventional

From 100 colorectal cancer patients being treated with FOLFIRI regimen or any kind of irinotecan containing regimen, blood samples for irinotecan and its metabolites levels and genotypes related with its metabolism will be collected. The association of their levels and genotypes and treatment effects will be evaluated.

NCT ID: NCT00506571 Recruiting - Secondary Clinical Trials

Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer

TIROX2
Start date: July 2007
Phase: Phase 2
Study type: Interventional

Patients will be treated with irinotecan (150 mg/m2) followed by oxaliplatin (85 mg/m2) on day 1 and S-1 (80 mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a planned treatment of maximum 12 cycles of chemotherapy. Response assessment will be performed every 2 cycles of chemotherapy.

NCT ID: NCT00506207 Active, not recruiting - Colorectal Neoplasm Clinical Trials

A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy

TIROX
Start date: September 2006
Phase: Phase 1
Study type: Interventional

This study is an open-label, single center, and a dose-escalating phase I study to determine the maximal tolerated dose and the recommended dose of S-1 combined with irinotecan/oxaliplatin in patients with unresectable or metastatic colorectal or gastric carcinoma.

NCT ID: NCT00506168 Terminated - Clinical trials for Colorectal Neoplasms

Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer

Start date: November 2001
Phase: Phase 2
Study type: Interventional

This study is to evaluate the efficacy and safety of combination chemotherapy with irinotecan and capecitabine in previously untreated metastatic colorectal cancer.